EUCTR2005-002842-20-DE进行中（未招募）不适用
Phase II dose ranging study to evaluate the anti-mycotic efficacy of topical Abafungin formulations in patients with tinea pedis. - N.A.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •man or woman aged 18 to 75 years;
- •presence of interdigital tinea pedis caused by dermatophytes on one or both feet, characterized by clinical evidence of involvement of more than one interdigital space and at least moderate erythema (at least score 2), and moderate scaling (at least score 2);
- •a confirmatory microscopic demonstration of fungal elements;
- •the physical examination must be without other disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
- •sexually active females of childbearing potential should use a medically accepted contraceptive regimen: systemic contraceptive (oral, implant, injection), diaphragm with intravaginal spermicide, cervical cap, intrauterine device (IUD), condom with intravaginal spermicide, or be surgically sterile (hysterectomy or tubal ligation);
- •written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •received treatments like foot or shoe powders, pharmaceutic and cosmetic topicals (e.g. creams/gels, except for washing products) or topical anti-fungal therapy of the feet within 30 days before study entry, oral antifungal therapies within three months before study entry (8 months for oral terbinafine), systemic antibiotic or corticosteroid treatment, topical corticosteroids within 30 days before study entry, radiation therapy and/or anti-neoplastic agents within one year before study entry;
- •receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks of the baseline visit;
- •receiving potassium permanganate drugs either concurrently or within 1 week of the baseline visit;
- •use of antibacterial, antiviral or antihelminthic drugs;
- •evidence of drug or alcohol abuse;
- •pregnancy or nursing;
- •have symptoms of a clinically significant illness, or known laboratory value deviation, that may influence the safety of the patient, or the outcome of the study in the 30 days before and during the study;
- •are known to be immunodeficient;
- •have symptoms of a diabetic foot or neuropathies;
- •have foot psoriasis, corn and/or callus involving any interdigital web spaces, atopic or contact dermatitis;
- •widespread dermatophytoses, plantar / moccasin type tinea pedis, hyperkeratotic tinea pedis, tinea pedis or systemic fungal infection requiring systemic treatment, onychomycosis, tinea corporis, tinea cruris or tinea capitis, mucocutaneous candidiasis or bacterial skin infection;
- •participation in another clinical trial involving pharmaceutical products in the 30 days preceding the study and during the study;
- •known allergic reactions or known hypersensitivity to components of the study medications;
- •in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e. g. due to probable noncompliance or inability to answer questions or to assess tolerability of the study drug or to understand the study and give adequately informed consent.
研究者
相似试验
进行中（未招募）
不适用
This is a clinical study designed to explore the safety, effectiveness and optimum dose of the medicine MED-563 in adult patients who suffer from asthma that is not fully controlled by other treatmentsncontrolled AsthmaMedDRA version: 14.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020126-17-BGAstraZeneca AB482
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) TherapyActive Systemic Lupus ErythematosusMedDRA version: 21.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-000328-16-DEAmgen Inc300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) TherapyActive Systemic Lupus ErythematosusMedDRA version: 21.1Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-000328-16-HUAmgen Inc300
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) TherapyActive Systemic Lupus ErythematosusMedDRA version: 20.0 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2019-000328-16-FRAmgen Inc300
进行中（未招募）
1 期
Phase II, dose ranging, efficacy study of anti-thymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes (T1D)EUCTR2019-003265-17-DKniversitair Ziekenhuis Leuven, Belgium114